Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Solengepras Suspension vs Tablet
NCT05635461Phase 1Completed
- Sponsor
- Cerevance
- Start
- Oct 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of solengepras in Parkinson's disease (PD) (3 arms), sponsored by Cerevance. Primary endpoints: Area Under the Concentration-time Curve From Time 0 to Last Non-Zero Concentration, Area Under the Plasma Concentration Time Curve From Time 0 to 96 Hours and 3 more. Started Oct 2022; status: completed.
02
Drugs
solengepras
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05635461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635461.